Trial Profile
Retrospective Study of Patient with Fabry Disease who Switched Therapies from Algasidase beta to Agalsidase alfa
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 23 Aug 2018
Price :
$35
*
At a glance
- Drugs Agalsidase alfa (Primary)
- Indications Fabry's disease
- Focus Adverse reactions; Therapeutic Use
- 23 Aug 2018 New trial record